Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 18/20 | 0.72 |
| ▸ | CNR2 | P34972 | 5/20 | 0.58 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.50 |
| ▸ | MARS1 | P56192 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6343454 | 0.88 | CNR1 (0.67) | CNR1CNR2GABRA2GABRB2MARS1 | |
| SCHEMBL6332950 | 0.87 | CNR1 (0.68) | CNR1CNR2GABRA2GABRB2MARS1 | |
| SCHEMBL4507104 | 0.84 | CNR1 (0.84) | CNR1CNR2 | |
| SCHEMBL5370038 | 0.84 | CNR1 (0.62) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL4516531 | 0.84 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL6343712 | 0.83 | CNR1 (0.61) | CNR1CNR2 | |
| SCHEMBL6334842 | 0.83 | CNR1 (0.61) | CNR1CNR2 | |
| SCHEMBL4510717 | 0.82 | CNR1 (0.65) | CNR1CNR2 | |
| SCHEMBL6334651 | 0.81 | CNR1 (0.85) | CNR1CNR2 | |
| SCHEMBL6334654 | 0.81 | CNR1 (0.85) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | CNR1 405/4885CNR2 340/4885GABRA2 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.